In our TCGA analysis, we observed that the GBM patient groups with high expression of PHGDH, PSAT1, and PSPH display higher expression of EGFR compared to those cases with lower expression of these serine/glycine metabolic enzymes (Fig. 4). This evidence concerns the gene EGFR and glioblastoma.